Swedencare Q4 revenue up 3%, EBITDA down 25%

Swedencare AB (publ)

12/02/2026 06:40

Overview

Sweden pet healthcare firm's Q4 revenue grew 3% yr/yr, operational EBITDA fell 25%

Profitability affected by marketing costs, ERP issues, and inventory write-offs

Outlook

Swedencare aims to complete Amazon transition for NaturVet and Europe by 2026

Company plans to expand collaborations in veterinary sector in Europe and North America

Swedencare proposes a dividend of 0.28 SEK per share for 2026

Result Drivers

MARKETING COSTS - Higher marketing expenses, especially on Amazon, impacted profitability as they did not align with expected sales increases

ERP IMPLEMENTATION - ERP transition at NaturVet caused operational disruptions, affecting execution speed and shipments

INVENTORY WRITE-OFFS - Inventory write-offs contributed to weaker profitability during the quarter

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
SEK 0.10
Q4 Net Income
SEK 16.40 mln
Q4 Adjusted EBITDA
SEK 108.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Swedencare AB (publ) is SEK49.00, about 112.6% above its February 11 closing price of SEK23.05

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 27 three months ago

Press Release: ID:nMFNbSw13J

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)